FDA’s Technology Modernization Action Plan
The plan describes important near-term actions that FDA is taking to modernize use of technology—computer hardware, software, data, and analytics—to advance FDA’s public health mission.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Roland Foods, LLC Initiates a Voluntary Recall of Roland Red Lumpfish Caviar and Roland Black Lumpfish Caviar Due to Possible Health Risk
Food & Beverages
Ridley Block Operations Voluntarily Recalls a Batch of Ultralyx 2416-5 No Other Products are Affected; Distribution was Limited to Georgia and Florida
Animal & Veterinary
Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP
FDA’s Comprehensive Response to HIV — Part II
FDA plays a pivotal role in advancing HIV therapies in underserved global markets through the President’s Emergency Plan for AIDS Relief (PEPFAR).
FDA’s Comprehensive Response to HIV — Part I
A multidisciplinary approach helps spur the development of effective treatments and approval of an expanding number of HIV drugs and drug combinations.
Delivering Promising New Medicines Without Sacrificing Safety and Efficacy
All drugs approved under the agency’s expedited programs are held to the same approval standards as other FDA drug approvals.
Biologics, Medical Devices
Cutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway